SOTIO

Prague, Czechia Founded: 2010 • Age: 16 yrs Acquired By PPF Group
Activated dendritic cells are developed for cancer immunotherapy treatments.
Request Access

About SOTIO

SOTIO is a company based in Prague (Czechia) founded in 2010 was acquired by PPF Group in June 2012. It operates as a Professional Services. SOTIO has completed 1 acquisition, including CytunePharma. SOTIO offers products and services including SOT106, SOT109, and Nanrilkefusp alfa. SOTIO operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.

  • Headquarter Prague, Czechia
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Sotio Biotech A.S.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $8.12 K (USD)
    0
    as on Dec 31, 2021
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
  • Acquired by
    PPF Group

    (Jun 01, 2012)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of SOTIO

SOTIO offers a comprehensive portfolio of products and services, including SOT106, SOT109, and Nanrilkefusp alfa. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

SOT106 is developed as an ADC targeting LRRC15.

SOT109 is designed to target cadherin-17 in cancers.

Nanrilkefusp alfa is developed for targeted immune activation.

People of SOTIO
Headcount 200-500
Employee Profiles 19
Board Members and Advisors 5
Employee Profiles
People
Samone V.
Associate Director, Accounting
People
Daniela Červená
Chief Accountant
People
Pavel Solský
Chief Financial & Commercial Officer
People
Jiří Lísal
COO

Unlock access to complete

Board Members and Advisors
people
Alise Reicin
Strategic Advisor
people
Josep Tabernero
Strategic Advisor
people
Anthony W. Tolcher
Strategic Advisor
people
Kapil Dhingra
Strategic Advisor

Unlock access to complete

Funding Insights of SOTIO

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in SOTIO

SOTIO has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include PPF Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
PPF Group is engaged in international investment across diverse sectors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by SOTIO

SOTIO has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CytunePharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Immunostimulatory agents and conjugated monoclonal antibodies for cancer are developed.
2007
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - SOTIO

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sotio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of SOTIO

SOTIO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
domain founded_year HQ Location
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about SOTIO

When was SOTIO founded?

SOTIO was founded in 2010.

Where is SOTIO located?

SOTIO is headquartered in Prague, Czechia.

Who is the current CEO of SOTIO?

Radek Spisek is the current CEO of SOTIO.

What is the annual revenue of SOTIO?

Annual revenue of SOTIO is $8.12K as on Dec 31, 2021.

What does SOTIO do?

SOTIO Biotech is engaged in the development of next-generation immunotherapies for cancer treatment. The companys pipeline includes internally developed and in-licensed candidates targeting various solid tumor types. Solutions such as antibody-drug conjugates and immunocytokines are being advanced through clinical development to provide safer and more effective treatments. The focus is placed on translating scientific innovation into patient benefits within the oncology sector.

Who are the top competitors of SOTIO?

SOTIO's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

What products or services does SOTIO offer?

SOTIO offers SOT106, SOT109, and Nanrilkefusp alfa.

How many acquisitions has SOTIO made?

SOTIO has made 1 acquisition, including CytunePharma.

Who are SOTIO's investors?

SOTIO has 1 investor. Key investors include PPF Group.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available